Y. Yarden and G. Pines, The ERBB network: at last, cancer therapy meets systems biology, Nature Reviews Cancer, vol.66, issue.8, pp.553-563, 2012.
DOI : 10.1038/nrc3309

F. Shi, S. Telesco, Y. Liu, R. Radhakrishnan, and M. Lemmon, ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation, Proc Natl Acad Sci, vol.27, pp.7692-7697, 2010.

T. Ben-kasus, B. Schechter, S. Lavi, Y. Yarden, and S. M. , Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: Relevance of receptor endocytosis, Proceedings of the National Academy of Sciences, vol.106, issue.9, pp.3294-3299, 2009.
DOI : 10.1073/pnas.0812059106

M. Campbell, D. Amin, and M. Moasser, HER3 Comes of Age: New Insights into Its Functions and Role in Signaling, Tumor Biology, and Cancer Therapy, Clinical Cancer Research, vol.16, issue.5, pp.1373-1383, 2010.
DOI : 10.1158/1078-0432.CCR-09-1218

R. Cook, J. Garrett, V. Sánchez, J. Stanford, Y. C. Chakrabarty et al., ErbB3 Ablation Impairs PI3K/Akt-Dependent Mammary Tumorigenesis, Cancer Research, vol.71, issue.11, pp.3941-3951, 2011.
DOI : 10.1158/0008-5472.CAN-10-3775

H. Friess, Y. Yamanaka, M. Kobrin, D. Do, M. Büchler et al., Enhanced erbB-3 expression in human pancreatic cancer correlates with tumor progression, Clin Cancer Res, vol.1, pp.1413-1420, 1995.

R. Naidu, M. Yadav, S. Nair, and M. Kutty, Expression of c-erbB3 protein in primary breast carcinomas, British Journal of Cancer, vol.78, issue.10, pp.1385-1390, 1998.
DOI : 10.1038/bjc.1998.689

B. Tanner, D. Hasenclever, K. Stern, W. Schormann, M. Bezler et al., ErbB-3 Predicts Survival in Ovarian Cancer, Journal of Clinical Oncology, vol.24, issue.26, pp.4317-4323, 2006.
DOI : 10.1200/JCO.2005.04.8397

M. Reschke, D. Mihic-probst, E. Van-der-horst, P. Knyazev, P. Wild et al., HER3 is a determinant for poor prognosis in melanoma, Clin Cancer Res, vol.14, pp.5188-5197, 2008.

M. Hayashi, M. Inokuchi, Y. Takagi, H. Yamada, K. Kojima et al., High expression of HER3 is associated with a decreased survival in gastric cancer, Clin Cancer Res, vol.14, pp.7843-7849, 2008.

A. Beji, D. Horst, J. Engel, T. Kirchner, and A. Ullrich, Toward the prognostic significance and therapeutic potential of HER3 receptor tyrosine kinase in human colon cancer, Clin Cancer Res, vol.18, pp.956-68, 2012.

A. Ho-pun-cheung, E. Assenat, C. Bascoul-mollevi, F. Bibeau, F. Boissière-michot et al., EGFR and HER3 mRNA expression levels predict distant metastases in locally advanced rectal cancer, Int J Cancer, vol.128, pp.2938-2946, 2011.

M. Narayan, J. Wilken, L. Harris, A. Baron, K. Kimbler et al., Trastuzumabinduced HER reprogramming in "resistant" breast carcinoma cells, Cancer Res, vol.69, pp.2191-2194, 2009.

D. Wheeler, S. Huang, T. Kruser, M. Nechrebecki, E. Armstrong et al., Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members, Oncogene, vol.27, pp.3944-3956, 2008.

J. Arnoletti, D. Buchsbaum, Z. Huang, A. Hawkins, M. Khazaeli et al., Mechanisms of resistance to Erbitux (anti-epidermal growth factor receptor) combination therapy in pancreatic adenocarcinoma cells, J Gastrointest Surg, vol.8, pp.960-969, 2004.

J. Engelman, K. Zejnullahu, T. Mitsudomi, Y. Song, C. Hyland et al., MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling, Science, vol.316, pp.1039-1043, 2007.

J. Garrett, M. Olivares, C. Rinehart, N. Granja-ingram, V. Sánchez et al., Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase, Proc Natl Acad Sci, vol.108, pp.5021-5026, 2011.

A. Chakrabarty, V. Sánchez, M. Kuba, C. Rinehart, and C. Arteaga, Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors, Proc Natl Acad Sci, vol.109, pp.2718-2723, 2011.

C. Desbois-mouthon, A. Baron, M. Blivet-van-eggelpoël, L. Fartoux, C. Venot et al., Insulin-Like Growth Factor-1 Receptor Inhibition Induces a Resistance Mechanism via the Epidermal Growth Factor Receptor/HER3/AKT Signaling Pathway: Rational Basis for Cotargeting Insulin-Like Growth Factor-1 Receptor and Epidermal Growth Factor Receptor in Hepatocellular Carcinoma, Clinical Cancer Research, vol.15, issue.17, pp.5445-5456, 2009.
DOI : 10.1158/1078-0432.CCR-08-2980

T. Kruser and D. Wheeler, Mechanisms of resistance to HER family targeting antibodies, Experimental Cell Research, vol.316, issue.7, pp.1083-1100, 2010.
DOI : 10.1016/j.yexcr.2010.01.009

E. Van-der-horst, M. Murgia, M. Treder, and A. Ullrich, Anti-HER-3 MAbs inhibit HER-3- mediated signaling in breast cancer cell lines resistant to anti-HER-2 antibodies, Int J Cancer, vol.115, pp.519-527, 2005.

B. Schoeberl, A. Faber, D. Li, M. Liang, K. Crosby et al., An ErbB3 antibody, MM- 121, is active in cancers with ligand-dependent activation, Cancer Res, vol.70, pp.2485-2494, 2010.

G. Sala, S. Traini, D. Egidio, M. Vianale, G. Rossi et al., An ErbB-3 antibody, MP-RM-1, inhibits tumor growth by blocking ligand-dependent and independent activation of ErbB-3/Akt signaling, Oncogene, vol.31, pp.1275-1286, 2012.

G. Schaefer, L. Haber, L. Crocker, S. Shia, L. Shao et al., A Two-in-One Antibody against HER3 and EGFR Has Superior Inhibitory Activity Compared with Monospecific Antibodies, Cancer Cell, vol.20, issue.4, pp.472-486, 2011.
DOI : 10.1016/j.ccr.2011.09.003

L. Aurisicchio, E. Marra, L. Luberto, F. Carlomosti, D. Vitis et al., Novel anti-ErbB3 monoclonal antibodies show therapeutic efficacy in xenografted and spontaneous mouse tumors, Journal of Cellular Physiology, vol.104, issue.10, pp.3381-3388, 2012.
DOI : 10.1002/jcp.24037

E. Blackburn, S. Zona, M. Murphy, I. Brown, S. Chan et al., A monoclonal antibody to the human HER3 receptor inhibits Neuregulin 1-beta binding and co-operates with Herceptin in inhibiting the growth of breast cancer derived cell lines, Breast Cancer Research and Treatment, vol.10, issue.1, pp.53-59, 2012.
DOI : 10.1007/s10549-011-1908-1

Q. Sheng, X. Liu, E. Fleming, K. Yuan, H. Piao et al., An Activated ErbB3/NRG1 Autocrine Loop Supports In Vivo Proliferation in Ovarian Cancer Cells, Cancer Cell, vol.17, issue.3, pp.298-310, 2010.
DOI : 10.1016/j.ccr.2009.12.047

J. Schmiedel, A. Blaukat, S. Li, T. Knöchel, and K. Ferguson, Matuzumab Binding to EGFR Prevents the Conformational Rearrangement Required for Dimerization, Cancer Cell, vol.13, issue.4, pp.365-373, 2008.
DOI : 10.1016/j.ccr.2008.02.019

N. Gaborit, C. Larbouret, J. Vallaghe, F. Peyrusson, C. Bascoul-mollevi et al., Time-resolved Fluorescence Resonance Energy Transfer (TR-FRET) to Analyze the Disruption of EGFR/HER2 Dimers: A NEW METHOD TO EVALUATE THE EFFICIENCY OF TARGETED THERAPY USING MONOCLONAL ANTIBODIES, Journal of Biological Chemistry, vol.286, issue.13, pp.11337-11345, 2011.
DOI : 10.1074/jbc.M111.223503
URL : https://hal.archives-ouvertes.fr/inserm-00576598

P. Mondon, N. Souyris, L. Douchy, F. Crozet, K. Bouayadi et al., Method for generation of human hyperdiversified antibody fragment library, Biotechnology Journal, vol.5, issue.1, pp.76-82, 2007.
DOI : 10.1002/biot.200600205

A. Talavera, R. Friemann, S. Gómez-puerta, C. Martinez-fleites, G. Garrido et al., Nimotuzumab, an Antitumor Antibody that Targets the Epidermal Growth Factor Receptor, Blocks Ligand Binding while Permitting the Active Receptor Conformation, Cancer Research, vol.69, issue.14, pp.5851-5859, 2009.
DOI : 10.1158/0008-5472.CAN-08-4518

S. Li, K. Schmitz, P. Jeffrey, J. Wiltzius, P. Kussie et al., Structural basis for inhibition of the epidermal growth factor receptor by cetuximab, Cancer Cell, vol.7, issue.4, pp.301-311, 2005.
DOI : 10.1016/j.ccr.2005.03.003

C. Larbouret, B. Robert, I. Navarro-teulon, S. Thèzenas, M. Ladjemi et al., In vivo Therapeutic Synergism of Anti-Epidermal Growth Factor Receptor and Anti-HER2 Monoclonal Antibodies against Pancreatic Carcinomas, Clinical Cancer Research, vol.13, issue.11, pp.3356-3362, 2007.
DOI : 10.1158/1078-0432.CCR-06-2302
URL : https://hal.archives-ouvertes.fr/inserm-00153693

B. Zhou, M. Peyton, B. He, C. Liu, L. Girard et al., Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer, Cancer Cell, vol.10, issue.1, pp.39-50, 2006.
DOI : 10.1016/j.ccr.2006.05.024

H. Farhan, C. Schuster, M. Klinger, E. Weisz, G. Waxenecke et al., Inhibition of Xenograft Tumor Growth and Down-Regulation of ErbB Receptors by an Antibody Directed against Lewis Y Antigen, Journal of Pharmacology and Experimental Therapeutics, vol.319, issue.3, pp.1459-1466, 2006.
DOI : 10.1124/jpet.106.107318

Q. Zhang, E. Park, K. Kani, and R. Landgraf, Functional isolation of activated and unilaterally phosphorylated heterodimers of ERBB2 and ERBB3 as scaffolds in ligand-dependent signaling, Proceedings of the National Academy of Sciences, vol.109, issue.33, 2012.
DOI : 10.1073/pnas.1200105109

H. Cho and D. Leahy, Structure of the Extracellular Region of HER3 Reveals an Interdomain Tether, Science, vol.297, issue.5585, pp.1330-1333, 2002.
DOI : 10.1126/science.1074611

K. Aird, X. Ding, A. Baras, J. Wei, M. Morse et al., Trastuzumab signaling in ErbB2-overexpressing inflammatory breast cancer correlates with X-linked inhibitor of apoptosis protein expression, Molecular Cancer Therapeutics, vol.7, issue.1, pp.38-47, 2008.
DOI : 10.1158/1535-7163.MCT-07-0370

J. Yang, C. Zong, W. Xia, H. Yamaguchi, Q. Ding et al., ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation, Nature Cell Biology, vol.9, issue.2, pp.138-148, 2008.
DOI : 10.1038/sj.onc.1200861

Y. Wu, X. Shang, M. Sarkissyan, D. Slamon, and J. Vadgama, FOXO1A Is a Target for HER2-Overexpressing Breast Tumors, Cancer Research, vol.70, issue.13, pp.5475-5485, 2010.
DOI : 10.1158/0008-5472.CAN-10-0176

S. Chandarlapaty, A. Sawai, M. Scaltriti, V. Rodrik-outmezgui, O. Grbovic-huezo et al., AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity, Cancer Cell, vol.19, issue.1, pp.58-71, 2011.
DOI : 10.1016/j.ccr.2010.10.031

W. Fu, Q. Ma, L. Chen, P. Li, M. Zhang et al., MDM2 Acts Downstream of p53 as an E3 Ligase to Promote FOXO Ubiquitination and Degradation, Journal of Biological Chemistry, vol.284, issue.21, pp.13987-14000, 2009.
DOI : 10.1074/jbc.M901758200

B. Eckelman, G. Salvesen, and F. Scott, Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family, EMBO reports, vol.273, issue.10, pp.988-994, 2006.
DOI : 10.1021/bi980893w

S. Huang, S. Benavente, E. Armstrong, C. Li, D. Wheeler et al., p53 Modulates Acquired Resistance to EGFR Inhibitors and Radiation, Cancer Research, vol.71, issue.22, pp.7071-7079, 2011.
DOI : 10.1158/0008-5472.CAN-11-0128

Z. Cao, X. Wu, Y. L. Sweeney, C. , C. Kl et al., Neuregulin-Induced ErbB3 Downregulation Is Mediated by a Protein Stability Cascade Involving the E3 Ubiquitin Ligase Nrdp1, Molecular and Cellular Biology, vol.27, issue.6, pp.2180-2188, 2007.
DOI : 10.1128/MCB.01245-06

X. Qiu and A. Goldberg, Nrdp1/FLRF is a ubiquitin ligase promoting ubiquitination and degradation of the epidermal growth factor receptor family member, ErbB3, Proceedings of the National Academy of Sciences, vol.99, issue.23, pp.14843-14848, 2002.
DOI : 10.1073/pnas.232580999